AstraZeneca Will Establish Antibiotic Subsidiary With $40 Million
This article was originally published in The Pink Sheet Daily
The big pharma – one of the few still investing in antibiotic research – will create a stand-alone subsidiary to focus exclusively on early-stage antibiotic development.
You may also be interested in...
AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.
The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.